Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenus Regulatory News (GNS)

Share Price Information for Genus (GNS)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,754.00
Bid: 1,762.00
Ask: 1,768.00
Change: -42.00 (-2.34%)
Spread: 6.00 (0.341%)
Open: 1,822.00
High: 1,822.00
Low: 1,750.00
Prev. Close: 1,796.00
GNS Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Appointment of Chief Executive Officer

22 Aug 2019 07:00

RNS Number : 8302J
Genus PLC
22 August 2019
 

For Immediate Release 22 August 2019

 

Genus plc('Genus', or the 'Company')

Appointment of Chief Executive Officer

Genus plc (LSE: GNS), a leading global animal genetics company, announces that Stephen Wilson, currently Group Finance Director, has been appointed by the Board as Chief Executive with effect from the close of business on 13 September 2019. This follows the announcement of 25 March 2019 that Karim Bitar will be stepping down from the Board and taking up the position of Chief Executive of another company.

Stephen has been with Genus since January 2013 and already has a very strong and deep understanding of Genus and has been an integral part of the team in the successful strategic and operational development of the Group in recent years, as it has continued to grow and strengthen its position as a world leader in animal genetics. Stephen was by far the strongest candidate for the role following a review of both external and internal candidates managed by an external search agency.

Stephen's current finance responsibilities will be undertaken by Janet Duane, currently Group Financial Controller on an interim basis. A search for a permanent replacement Group Finance Director has already been initiated by an external agency.

Bob Lawson, Chairman of Genus, commented on Stephen's appointment;

"Genus is extremely fortunate to have such a strong individual in Stephen Wilson to fill the role of Chief Executive. Stephen has already had significant strategic and operational input in the development of Genus and no one knows the business better than him.

"We are delighted that Stephen will drive Genus through the next stage of our continued growth, and it is clear that Genus is, and will continue to be, in strong hands."

Genus

Tel: +44(0)1256 345970

Bob Lawson, Chair

Stephen Wilson, Group Finance Director

Buchanan

Tel: +44(0)207 466 5000

Charles Ryland /Chris Lane/Sophie Wills

This announcement is available on the Genus website www.genusplc.com

About Genus

Genus is a world-leading animal genetics company. Genus creates advances to animal breeding and genetic improvement by applying biotechnology and sells added value products for livestock farming and food producers. Its technology is applicable across livestock species and is currently commercialised by Genus in the dairy, beef and pork food production sectors.

Genus's worldwide sales are made in over seventy-five countries under the trademarks 'ABS' (dairy and beef cattle) and 'PIC' (pigs) and comprise semen, embryos and breeding animals with superior genetics to those animals currently in farms. Genus's customers' animals produce offspring with greater production efficiency, and quality, and use these to supply the global dairy and meat supply chains.

The Group's competitive edge has been created from the ownership and control of proprietary lines of breeding animals, the biotechnology used to improve them and its global supply chain, technical service and sales and distribution network.

With headquarters in Basingstoke, United Kingdom, Genus companies operate in over twenty-five countries on six continents, with research laboratories located in Madison, Wisconsin, USA.

Regulatory Notes

Details of any payments to be made to Stephen Wilson will be disclosed in full in the Company's 2019 Directors' Remuneration Report. Any such terms will be consistent with the Company's approved Directors' Remuneration Policy.

 

This announcement is made in accordance with Listing Rule 9.6.11R. There are no matters to be disclosed in connection with Listing Rule 9.6.13R (2) - (6).

 

This announcement contains inside information for the purposes of Article 7 of Regulation 596/2014. The person responsible for making this announcement on behalf of the Group is Dan Hartley (General Counsel and Company Secretary).

 

As noted, Janet Duane will be appointed the Company's interim Group Finance Director. Given the interim nature of the role, Janet will not be appointed as an executive Director of the Company, but will be treated as a person discharging managerial responsibility.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
BOALLFLETDILFIA
Date   Source Headline
3rd Feb 202010:51 amRNSBlock listing Interim Review
23rd Jan 20203:52 pmRNSNotification of Major Holdings
2nd Jan 202010:02 amRNSTotal Voting Rights
12th Dec 20192:17 pmRNSNOTIFICATION OF MAJOR HOLDINGS
2nd Dec 20194:45 pmRNSTotal Voting Rights
20th Nov 20197:00 amRNSAppointment of Chief Financial Officer
15th Nov 20196:18 pmRNSDirector/PDMR Shareholding
14th Nov 20191:23 pmRNSResult of AGM
14th Nov 20197:00 amRNSAGM TRADING UPDATE
1st Nov 201912:05 pmRNSTotal Voting Rights
14th Oct 20198:00 amRNSAnnual Report and Annual General Meeting
10th Oct 20193:30 pmRNSDirector/PDMR Shareholding
3rd Oct 20193:06 pmRNSNOTIFICATION OF MAJOR HOLDINGS
2nd Oct 20193:38 pmRNSNotification of Major Holdings
1st Oct 20195:23 pmRNSTotal Voting Rights
20th Sep 201912:38 pmRNSDirector/PDMR Shareholding
18th Sep 20196:09 pmRNSDirector/PDMR Shareholding
17th Sep 20191:24 pmRNSDirector/PDMR Shareholding
12th Sep 20192:59 pmRNSDirector/PDMR Shareholding
11th Sep 20198:02 amRNSCORRECTION: Outcome of IntelliGen Litigation
11th Sep 20197:00 amRNSOutcome of latest IntelliGen Litigation
10th Sep 20197:00 amRNSOUTCOME IN LATEST INTELLIGEN LITIGATION
5th Sep 20197:00 amRNSPreliminary Results
22nd Aug 20197:00 amRNSAppointment of Chief Executive Officer
1st Aug 20195:49 pmRNSBlock listing Interim Review
1st Aug 20195:46 pmRNSTotal Voting Rights
30th Jul 201912:12 pmRNSNOTIFICATION OF MAJOR HOLDINGS
9th Jul 20195:12 pmRNSNotification of Major Holdings
3rd Jul 20197:00 amRNSNotification of Major Holdings
1st Jul 20191:45 pmRNSTotal Voting Rights
18th Jun 20193:29 pmRNSNotification of Major Holdings
3rd Jun 20195:43 pmRNSTotal Voting Rights
24th May 20196:03 pmRNSDirector/PDMR Shareholding
16th May 20199:58 amRNSStrategic porcine collaboration in China
1st Apr 20191:54 pmRNSTotal Voting Rights
25th Mar 20197:00 amRNSGenus Chief Executive Transition
4th Mar 20193:11 pmRNSDirector/PDMR Shareholding
1st Mar 20192:00 pmRNSTotal Voting Rights
28th Feb 20197:00 amRNSInterim Results
1st Feb 20192:00 pmRNSBlock listing Interim Review
2nd Jan 20192:49 pmRNSTotal Voting Rights
11th Dec 20181:37 pmRNSDirector/PDMR Shareholding
7th Dec 20187:00 amRNSResult of placing to raise approximately £68m
6th Dec 20184:41 pmRNSProposed placing to raise approximately £68m
21st Nov 201812:00 pmRNSDirector Declaration
15th Nov 20184:00 pmRNSResult of AGM
15th Nov 20187:00 amRNSAGM Trading Update
1st Nov 20182:00 pmRNSTotal Voting Rights
12th Oct 20184:53 pmRNSAnnual Report and Annual General Meeting
12th Oct 20184:37 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.